Eli Lilly announced that it will file for regulatory approval of its obesity drug retatrutide in the first quarter of 2027, following positive results from two late-stage trials. The company previously aimed to submit an application this year but requires additional time to finalize manufacturing and quality-control data.
In the trials, retatrutide demonstrated substantial weight loss, with participants losing an average of 20.8% to 22.6% of their body weight over 80 weeks, and showed improvements in blood sugar levels for adults with obesity and Type 2 diabetes, as well as those with cardiovascular disease.
The drug's side effects were consistent with other treatments in the GLP-1 class, primarily including diarrhea, nausea, and constipation. With five successful late-stage trials, Lilly is positioning retatrutide as a key component of its obesity portfolio, alongside its existing products Zepbound and Foundayo.
Analysts from TD Cowen project that retatrutide could generate $3.8 billion in sales by 2030, emphasizing its importance in maintaining Lilly's market share against competitors like Novo Nordisk in a sector expected to reach $100 billion by the 2030s. Retatrutide's unique mechanism targets multiple hormones, potentially offering more effective appetite control compared to existing treatments